Key result
Cardioneuroablation is linked to reduced autonomic activity and fewer arrhythmias at 2 years.
Why the study?
Cardioneuroablation treats disorders with increased vagal tone, but potential reinnervation during the first year could restore vagal hyperactivity. This study aimed to verify the degree of vagal denervation in the chronic phase and investigate post-ablation arrhythmias.
Does cardioneuroablation provide sustained vagal denervation and reduce arrhythmias in patients with vagal paroxysmal atrial fibrillation or neurocardiogenic syncope?
Cohort (n=83)
Does cardioneuroablation provide sustained vagal denervation and reduce arrhythmias in patients with vagal paroxysmal atrial fibrillation or neurocardiogenic syncope?
p-value: p=<0.001
Cardioneuroablation provides sustained vagal denervation up to 2 years without evidence of reinnervation, significantly reducing arrhythmias in patients with vagal AF or neurocardiogenic syncope.
May support durable autonomic effects in vagal AF; leaves open arrhythmia benefit confirmation in randomized trials.
Background: Several disorders present reflex or persistent increase in vagal tone that may cause refractory symptoms even in a normal heart patient. Cardioneuroablation, the vagal denervation by radiofrequency ablation of the neuromyocardial interface, was developed to treat these conditions without pacemaker implantation. A theoretical limitation could be the reinnervation, that naturally grows in the first year, that could recover the vagal hyperactivity. This study aims to verify the vagal denervation degree in the chronic phase after cardioneuroablation. Additionally, it intends to investigate the arrhythmias behavior after cardioneuroablation. Methods: Prospective longitudinal study with intrapatient comparison of 83 very symptomatic cases without significant cardiopathy, submitted to cardioneuroablation, 49 (59%) male, 47.3±17 years old, having vagal paroxysmal atrial fibrillation 58 (70%) or neurocardiogenic syncope 25 (30%), New York Heart Association class<II and absence of significant comorbidities. Cardioneuroablation was performed in both atria by interatrial septum puncture, with irrigated conventional catheter and electroanatomic reconstruction. Ablation targeted the neuromiocardial interface by fragmentation mapping (AF-Nests) using the velocity fractionation software, conventional recording, and anatomic localization of the ganglionated plexi. Heart rate variability (time and frequency domain) and arrhythmias were compared by 24h-Holter, before, and 1 year and 2 years after cardioneuroablation. In a 40 month follow-up, 80% of patients were asymptomatic. Results: Time- and frequency-domain heart rate variability demonstrated significant decrease in all autonomic parameters, showing an important parasympathetic and sympathetic activity reduction at 2-year post-cardioneuroablation ( P <0.001). There was no difference in heart rate variability between the 1-year and 2-year post-cardioneuroablation ( P >0.05) suggesting that the reinnervation has halted. There was also an important reduction in all bradyarrhythmias and tachyarrhythmias pre-cardioneuroablation versus post-cardioneuroablation ( P <0.01). Conclusions: There is an important and significant vagal and sympathetic denervation after 2 years of cardioneuroablation with a significant reduction in bradyarrhythmia and tachyarrhythmia in the whole group. There were no complications.
No takes yet. Share an insight, caveat, or question.
Pachón-M et al. (2020) conducted a cohort in Vagal paroxysmal atrial fibrillation or neurocardiogenic syncope (n=83). Cardioneuroablation vs. Pre-cardioneuroablation (baseline) was evaluated on Heart rate variability (time and frequency domain) and arrhythmias (p=<0.001). Cardioneuroablation significantly reduced parasympathetic and sympathetic activity at 2 years (P<0.001) and decreased both bradyarrhythmias and tachyarrhythmias (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: